Cambridge trials ‘world-first’ AI-designed vaccine

TL;DR:

  • A University of Cambridge team says it is the first to design a vaccine’s key component entirely with AI and trial it in people.
  • The vaccine targets all coronaviruses, aiming to protect even against strains that mutate or jump from animals.
  • Early human trials in 39 people tested safety; a larger study of around 200 will gauge immune response.

British researchers have used artificial intelligence to design what they call a “fundamentally new” type of vaccine, one engineered to guard against entire families of viruses rather than a single strain. The University of Cambridge team fed AI the genetic codes of a range of coronaviruses gathered by surveillance programmes, and the system designed a “super-antigen” intended to train the immune system against the whole family — including variants that mutate or new infections crossing from animals to humans.

Getting ahead of the next pandemic

Conventional vaccines are built around a current strain, which is why Covid and flu jabs need frequent updates. “We’re always behind,” said Prof Jonathan Heeney, who leads the work; the goal is to “get ahead of the curve”. The first trials, in 39 people, were designed to test safety, with a follow-up study of about 200 to assess how well the vaccine trains the immune system. Researchers described the immune impact so far as “modest” but encouraging, and the findings appear in the Journal of Infection. The team is already applying the approach to universal flu, H5N1 bird flu and viral haemorrhagic fevers including Ebola.

Independent experts struck a measured note. Prof Andy Pollard of the Oxford Vaccine Group, not involved in the study, called the animal data “fascinating” while stressing that human immune systems — shaped by years of past infection — are the real test. The work adds a concrete public-health example to a week dominated by AI’s risks, complementing UK research efforts such as the new Imperial and CNRS AI lab tackling metabolic disease.

Looking forward

If larger trials confirm a durable immune response, AI-designed antigens could compress vaccine development timelines and strengthen pandemic preparedness — a tangible upside for the UK’s life-sciences sector. For now, the science is early, but it signals AI moving from the lab bench into clinical trials.

Share this article